1、IN PARTNERSHIP WITHUnleashing the Power of Artificial Intelligence in Clinical TrialsRevolutionizing Drug Development3REVOLUTIONIZING DRUG DEVELOPMENT01020304TABLE OF CONTENTSForeword AI in Clinical Trials An ongoing revolution.Real-world impact Transformative AI Use Cases across the Clinical Trial

2、value chain.Fueling innovation The expanding ecosystem of AI-Driven Trials.Challenges ahead Overcoming barriers and limitations.Revolutionizing Drug DevelopmentWE ACCELERATE DATA AND AI ADOPTION TO POSITIVELY IMPACT PEOPLE AND ORGANIZATIONS.Artefact is a global leader in consulting services,speciali

3、zed in data transformation and data&digital marketing,from strategy to the deployment of AI solutions.We are offering a unique combination of innovation(Art)and data science(Fact).DATA READINESS|AI ACCELERATION|DATA&DIGITAL MARKETING|TECHNOLOGIES22COUNTRIES+1000CLIENTS1500EMPLOYEESUnleashing the Pow

4、er of Artificial Intelligence in Clinical TrialsThomas Filaire Partner-Healthcare Data&AI Transformation45REVOLUTIONIZING DRUG DEVELOPMENTREVOLUTIONIZING DRUG DEVELOPMENTPatientsthousandsForeword AI in Clinical TrialsAn ongoing revolution.0 1FOREWORD AI IN CLINICAL TRIALS-AN ONGOING REVOLUTIONHoweve

5、r,this process has reached a tipping point.In stark contrast to the rapid advancements in computing power described by Moores Law,the pharmaceutical industry has grappled with a phenomenon known as Erooms Law.This inverse trend highlights the escalating costs and complexities associated with drug de

6、velopment over time.While Moores Law predicts an exponential growth in computing capabilities,Erooms Law observes a doubling of drug development costs approximately every nine years.This reality is evidenced by the surge in average development costs from an estimated$900 million in 2012 to a stagger